Circle33 has acquired all the patents, technology and assets of Avaxia Biologics for the development of orally administered, gut-targeted antibody therapeutics

Compelling market opportunity in adult and pediatric IBD estimated at approximately $9B worldwide with several additional applications

Circle33 is currently entertaining business arrangements to sell or license its technology for commercialization of these assets

To know more please contact us through email